Rossella Fioravanti

List of Publications by Year
in descending order

42 papers	1,890 citations	318942 23 h-index	286692 43 g-index
48 all docs	48 docs citations	48 times ranked	3024 citing authors

#	Article	IF	Citations
1	Heterocycle-containing tranylcypromine derivatives endowed with high anti-LSD1 activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 973-985.	2.5	2
2	Effects of Structurally Different HDAC Inhibitors against Trypanosoma cruzi, Leishmania, and Schistosoma mansoni. ACS Infectious Diseases, 2022, 8, 1356-1366.	1.8	13
3	Novel Pyridineâ€Based Hydroxamates and 2â€²â€Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity. ChemMedChem, 2021, 16, 989-999.	1.6	8
4	CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas. Frontiers in Pharmacology, 2020, 11, 1230.	1.6	20
5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells. ACS Medicinal Chemistry Letters, 2020, 11, 977-983.	1.3	49
6	Targeting histone acetylation/deacetylation in parasites: an update (2017â€“2020). Current Opinion in Chemical Biology, 2020, 57, 65-74.	2.8	35
7	Novel Quinoline Compounds Active in Cancer Cells through Coupled DNA Methyltransferase Inhibition and Degradation. Cancers, 2020, 12, 447.	1.7	8
8	Tranylcypromineâ€Based LSD1 Inhibitors: Structureâ€Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation. ChemMedChem, 2020, 15, 643-658.	1.6	18
9	Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acidâ€induced differentiation. Science Advances, 2020, 6, eaax2746.	4.7	56
10	Histone Deacetylases Contribute to Excitotoxicity-Triggered Degeneration of Retinal Ganglion Cells In Vivo. Molecular Neurobiology, 2019, 56, 8018-8034.	1.9	20
11	Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells. Clinical Epigenetics, 2019, 11, 68.	1.8	30
12	Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. Current Opinion in Chemical Biology, 2019, 50, 89-100.	2.8	23
13	Design, Synthesis, Antiviral Evaluation, and SAR Studies of New 1-(Phenylsulfonyl)-1H-Pyrazolâ˜4-yl-Methylaniline Derivatives. Frontiers in Chemistry, 2019, 7, 214.	1.8	19
14	Six Years (2012â€“2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2â€Pyridone Compounds. Chemical Record, 2018, 18, 1818-1832.	2.9	76
15	Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation. European Journal of Medicinal Chemistry, 2017, 141, 15-25.	2.6	19
16	(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors. European Journal of Medicinal Chemistry, 2016, 117, 292-300.	2.6	30
17	3-(Phenyl-4-oxy)-5-phenyl-4,5-dihydro-(1 H)-pyrazole: A fascinating molecular framework to study the enantioseparation ability of the amylose (3,5-dimethylphenylcarbamate) chiral stationary phase. Part I. Structure-enantioselectivity relationships. Journal of Chromatography A, 2016, 1467, 221-227.	1.8	13
18	N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2401-2404.	1.0	21

#	Article	IF	Citations
19	A chromatographic and computational study on the driving force operating in the exceptionally large enantioseparation of N-thiocarbamoyl-3-(4â€²-biphenyl)-5-phenyl-4,5-dihydro-(1H) pyrazole on a 4-methylbenzoate cellulose-based chiral stationary phase. Journal of Chromatography A, 2014, 1324, 71-77.	1.8	20
20	Design, synthesis, and in vitro hMAO-B inhibitory evaluation of some 1-methyl-3,5-diphenyl-4,5-dihydro-1H-pyrazoles. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5128-5130.	1.0	11
21	1,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors. European Journal of Medicinal Chemistry, 2013, 59, 91-100.	2.6	28
22	Effects of polyphenol compounds on influenza A virus replication and definition of their mechanism of action. Bioorganic and Medicinal Chemistry, 2012, 20, 5046-5052.	1.4	43
23	Computer-Aided Molecular Design of Asymmetric Pyrazole Derivatives with Exceptional Enantioselective Recognition toward the Chiralcel OJ-H Stationary Phase. Journal of Chemical Information and Modeling, 2012, 52, 649-654.	2.5	23
24	Homoisoflavonoids: Natural Scaffolds with Potent and Selective Monoamine Oxidase-B Inhibition Properties. Journal of Medicinal Chemistry, 2011, 54, 2155-2164.	2.9	89
25	A chromatographic study on the exceptional enantioselectivity of cellulose tris(4-methylbenzoate) towards C5-chiral 4,5-dihydro-(1H)-pyrazole derivatives. Journal of Chromatography A, 2011, 1218, 5653-5657.	1.8	13
26	Use of cyclodextrins in biotransformation reactions with cell cultures ofMorus nigra: biosynthesis of prenylated chalcone isocordoin. Biotechnology and Applied Biochemistry, 2010, 56, 77-84.	1.4	3
27	Synthesis and biological evaluation of N-substituted-3,5-diphenyl-2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors. European Journal of Medicinal Chemistry, 2010, 45, 6135-6138.	2.6	103
28	A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 1273-1279.	1.4	83
29	Synthesis and molecular modelling studies of prenylated pyrazolines as MAO-B inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6479-6482.	1.0	21
30	Focusing on new monoamine oxidase inhibitors. Expert Opinion on Therapeutic Patents, 2010, 20, 909-939.	2.4	72
31	Unusually high enantioselectivity in high-performance liquid chromatography using cellulose tris(4-methylbenzoate) as a chiral stationary phase. Journal of Chromatography A, 2009, 1216, 4673-4678.	1.8	23
32	Chalcones: A Valid Scaffold for Monoamine Oxidases Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 2818-2824.	2.9	162
33	A Novel Histone Acetyltransferase Inhibitor Modulating Gcn5 Network: 530-536.	2.9	110
34	Synthesis, molecular modeling studies and selective inhibitory activity against MAO of N1-propanoyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives. European Journal of Medicinal Chemistry, 2008, 43, 2262-2267.	2.6	46
35	Monoamine Oxidase Isoform-Dependent Tautomeric Influence in the Recognition of 3,5-Diaryl Pyrazole Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 425-428.	2.9	65
36	Synthesis and in vitro activity of 2-thiazolylhydrazone derivatives compared with the activity of clotrimazole against clinical isolates of Candida spp.. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4635-4640.	1.0	67

#	Article	IF	Citations
37	Synthesis of some pyrazole derivatives and preliminary investigation of their affinity binding to P-glycoprotein. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4632-4635.	1.0	118
38	Recent development of monoamine oxidase inhibitors. Expert Opinion on Therapeutic Patents, 2005, 15, 1763-1782.	2.4	36
39	New pyrrole derivatives as antimycobacterial agents analogs of BM212. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2983-2988.	1.0	74
40	Antimycobacterial activity of new ortho-, meta- and para-toluidine derivatives. Il Farmaco, 1999, 54, 721-727.	0.9	11
41	Bactericidal Activities of the Pyrrole Derivative BM212 against Multidrug-Resistant and Intramacrophagic Mycobacterium tuberculosis Strains. Antimicrobial Agents and Chemotherapy, 1998, 42, 3035-3037.	1.4	156
42	Antifungal Agents, Part 11: Biphenyl Analogues of Naftifine: Synthesis and Antifungal Activities. Archiv Der Pharmazie, 1995, 328, 667-672.	2.1	5